Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Mesenchymal stem cells have been recently described to localize to breast carcinomas, where they integrate into the tumour-associated stroma. However, the involvement of mesenchymal stem cells (or their derivatives) in tumour pathophysiology has not been addressed. Here, we demonstrate that bone-marrow-derived human mesenchymal stem cells, when mixed with otherwise weakly metastatic human breast carcinoma cells, cause the cancer cells to increase their metastatic potency greatly when this cell mixture is introduced into a subcutaneous site and allowed to form a tumour xenograft. The breast cancer cells stimulate de novo secretion of the chemokine CCL5 (also called RANTES) from mesenchymal stem cells, which then acts in a paracrine fashion on the cancer cells to enhance their motility, invasion and metastasis. This enhanced metastatic ability is reversible and is dependent on CCL5 signalling through the chemokine receptor CCR5. Collectively, these data demonstrate that the tumour microenvironment facilitates metastatic spread by eliciting reversible changes in the phenotype of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MSC can be mobilized and recruited to active tumor sites, where they can incorporate into the tumor’s microenvironment [5, 68, 100–103].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“CCL5 can be secreted by both BM-MSC and ASC [100, 144] and displays pro-proliferative activities on breast cancer cell lines [145, 146].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“Another MSC-secreted pro-metastasis cytokine, CCL5 (RANTES), can be secreted upon interaction with cancer cells and is associated with tumor progression and invasion in various cancers [73, 87, 100, 142–144].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [100]
In the citing paper
“The injection of bone marrow-derived MSCs into tumour-bearing mice has demonstrated that they can become CAFs40”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [40]
In the citing paper
“CAFs comprise the majority of cell types within the TME, and their reciprocal interactions with cancer cells have been well documented (Whiteside, 2008; Hazlehurst et al., 2003; Karnoub et al., 2007).”
From Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism (2016) · cites this paper as Karnoub et al., 2007
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Self-citationCreation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Self-citationCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Bissell, M. J., & Radisky, D. (2001) · Nature Reviews Cancer · doi:10.1038/35094059 · Cited by 2,180
Molecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Self-citationHuman Bone Marrow–Derived Mesenchymal Stem Cells in the Treatment of Gliomas
Nakamizo, A., Marini, F., Amano, T., Khan, A., Studeny, M., Gumin, J., Chen, J., Hentschel, S., Vecil, G., Dembinski, J., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1874 · Cited by 1,035
(2002) · PubMed · Cited by 903
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
Elenbaas, B., Spirio, L., Koerner, F., Fleming, M. D., Zimonjic, D. B., Donaher, J. L., Popescu, N. C., Hahn, W. C., & Weinberg, R. A. (2001) · Genes & Development · doi:10.1101/gad.828901 · Cited by 878
Self-citation
Cited by
Items 601–700 of 1,024
Bassi, Ê. J., de Almeida, D. C., Moraes‐Vieira, P. M., & Câmara, N. O. S. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9311-1 · Cited by 122
“[108] showed that breast cancer cells stimulated the secretion of CCL5 by MSCs, which in turn acted on the cancer cells to enhance their motility, invasion and metastasis.”
De Luca, A., Gallo, M., Aldinucci, D., Ribatti, D., Lamura, L., D'Alessio, A., De Filippi, R., Pinto, A., & Normanno, N. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22548 · Cited by 113
“Angiogenesis is a rate-limiting process in tumor growth (Ferrara and Kerbel, 2005; Kerbel, 2008).”
BackgroundBreast cancer by proxy: can the microenvironment be both the cause and consequence?
Rønnov-Jessen, L., & Bissell, M. J. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.11.001 · Cited by 105
Increasing recognition of the importance of aldehyde oxidase in drug development and discovery
Garattini, E., & Terao, M. (2011) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.560606 · Cited by 111
The clusterin paradigm in prostate and breast carcinogenesis
Rizzi, F., & Bettuzzi, S. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0140 · Cited by 105
“The possible anti-cancer activity of green tea catechins (GTCs) may be explained by a number of different mechanisms extensively reviewed by Khan et al. (2006).”
BackgroundKawase, T., Yasui, Y., Nishina, S., Hara, Y., Yanatori, I., Tomiyama, Y., Nakashima, Y., Yoshida, K., Kishi, F., Nakamura, M., et al. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0340-0 · Cited by 111
Loss of Wwox drives metastasis in triple-negative breast cancer by JAK2/STAT3 axis
Chang, R., Song, L., Xu, Y., Wu, Y., Dai, C., Wang, X., Sun, X., Hou, Y., Li, W., Zhan, X., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05852-8 · Cited by 117
Lee, M. W., Ryu, S., Kim, D. S., Lee, J. W., Sung, K. W., Koo, H. H., & Yoo, K. H. (2019) · Leukemia · doi:10.1038/s41375-018-0373-9 · Cited by 121
Recent advances in regenerative medicine strategies for cancer treatment
Mansouri, V., Beheshtizadeh, N., Gharibshahian, M., Sabouri, L., Varzandeh, M., & Rezaei, N. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111875 · Cited by 121
p53 Status in Stromal Fibroblasts Modulates Tumor Growth in an SDF1-Dependent Manner
Addadi, Y., Moskovits, N., Granot, D., Lozano, G., Carmi, Y., Apte, R. N., Neeman, M., & Oren, M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1146 · Cited by 108
“A direct pro-metastatic effect of CAFs, through mechanism(s) involving the chemokine CCL5, was recently reported for mesenchymal stem cells co-injected into mice together with breast cancer cells [5].”
BackgroundBone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5
Nishikawa, G., Kawada, K., Nakagawa, J., Toda, K., Ogawa, R., Inamoto, S., Mizuno, R., Itatani, Y., & Sakai, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1508-2 · Cited by 112
Frisbie, L., Buckanovich, R. J., & Coffman, L. (2022) · Stem Cells · doi:10.1093/stmcls/sxac036 · Cited by 101
Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ
Sharma, M., Beck, A. H., Webster, J. A., Espinosa, I., Montgomery, K., Varma, S., van de Rijn, M., Jensen, K. C., & West, R. B. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0654-0 · Cited by 107
“On the other hand, researchers have found evidence that the stroma can play a more active role in the induction or promotion of oncogenesis [14, 22–25].”
BackgroundLiu, L., Liu, L., Yao, H. H., Zhu, Z., Ning, Z. L., & Huang, Q. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159947 · Cited by 120
“Moreover, cancer-associated fibroblasts secrete a number of growth factors and inflammatory chemokines that stimulate proliferation in cancer cells, enhance angiogenesis and epithelial-mesenchymal transition, and eventually accelerate cancer growth in addition to local and distant metastasis [36,37].”
BackgroundThe future of mesenchymal stem cell-based therapeutic approaches for cancer – From cells to ghosts
Mohr, A., & Zwacka, R. M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.025 · Cited by 120
Elboğa, U., Şahin, E., Kuş, T., Çayırlı, Y. B., Aktaş, G., Uzun, E., Çınkır, H. Y., Teker, F., Sever, Ö. N., Aytekin, A., et al. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01672-x · Cited by 119
Peng, C., & Li, Y. (2010) · Journal of Nanomaterials · doi:10.1155/2010/676839 · Cited by 119
“As the origins of the invasive and metastatic phenotypes of carcinoma cells have been the subjects of intense investigation [66], a new model for visualizing the metastasis is needed.”
BackgroundOncologic Trogocytosis of an Original Stromal Cells Induces Chemoresistance of Ovarian Tumours
Rafii, A., Mirshahi, P., Poupot, M., Faussat, A.-M., Simon, A., Ducros, E., Mery, E., Couderc, B., Lis, R., Capdet, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003894 · Cited by 106
“have recently provided evidence that bone-marrow-derived human mesenchymal stem cells caused, through paracrine mechanism, weakly metastatic human breast carcinoma cells to increase their metastatic potency [32].”
BackgroundClinical Applications of Mesenchymal Stem Cells in Chronic Diseases
Farini, A., Sitzia, C., Erratico, S., Meregalli, M., & Torrente, Y. (2014) · Stem Cells International · doi:10.1155/2014/306573 · Cited by 105
“Unfortunately,MSCs have been reported to promote tumor growth [152] andmetastases [153].”
The impact of tumor stroma on drug response in breast cancer
Dittmer, J., & Leyh, B. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.05.006 · Cited by 120
Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics
Lin, Q., & Yun, Z. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.12.12347 · Cited by 118
Development of sarcomas in mice implanted with mesenchymal stem cells seeded onto bioscaffolds
Tasso, R., Augello, A., Carida’, M., Postiglione, F., Tibiletti, M. G., Bernasconi, B., Astigiano, S., Fais, F., Truini, M., Cancedda, R., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgn234 · Cited by 111
Stem Cells Loaded with Nanoparticles as a Drug Carrier for In Vivo Breast Cancer Therapy
Cao, B., Yang, M., Zhu, Y., Qu, X., & Mao, C. (2014) · Advanced Materials · doi:10.1002/adma.201401550 · Cited by 113
Recent discoveries concerning the tumor - mesenchymal stem cell interactions
Lazennec, G., & Lam, P. Y. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.10.004 · Cited by 117
“engineered to express the thymidine kinase of the herpes simplex virus (HSV-Tk) under the control of RANTES (CCL5) promoter, which is highly active in MSCs in the tumor context [3].”
BackgroundConforti, R., Ma, Y., Morel, Y., Paturel, C., Terme, M., Viaud, S., Ryffel, B., Ferrantini, M., Uppaluri, R., Schreiber, R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1890 · Cited by 108
Cancer in Light of Experimental Evolution
Sprouffske, K., Merlo, L. M. F., Gerrish, P. J., Maley, C. C., & Sniegowski, P. (2012) · Current Biology · doi:10.1016/j.cub.2012.06.065 · Cited by 118
Mesenchymal stem cell-mediated transfer of mitochondria: mechanisms and functional impact
Velarde, F., Ezquerra, S., Delbruyere, X., Caicedo, A., Hidalgo, Y., & Khoury, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04207-3 · Cited by 118
Dufourcq, P., Descamps, B., Tojais, N. F., Leroux, L., Oses, P., Daret, D., Moreau, C., Lamazière, J. D., Couffinhal, T., & Duplàa, C. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0372 · Cited by 117
De Boeck, A., Hendrix, A., Maynard, D., Van Bockstal, M., Daniëls, A., Pauwels, P., Gespach, C., Bracke, M., & De Wever, O. (2013) · PROTEOMICS · doi:10.1002/pmic.201200179 · Cited by 105
“Bone marrow-derived mesenchymal stem cells (MSC) develop myofibroblast characteristics in response to TGF- 1 [6] and localize to solid tumors after intravenous administration in animal models [7, 8].”
BackgroundMycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells
Raghuvanshi, S., Sharma, P., Singh, S., Kaer, L. V., & Das, G. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1007967107 · Cited by 117
“These cells can also be recruited to sites of neoplasia, where they can promote metastatic spread of cancer cells (22).”
BackgroundRazmkhah, M., Jaberipour, M., Erfani, N., Habibagahi, M., Talei, A.-R., & Ghaderi, A. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2010.09.005 · Cited by 116
Role of MSC in the Tumor Microenvironment
Hass, R. (2020) · Cancers · doi:10.3390/cancers12082107 · Cited by 116
“Moreover, the CCL5 production of MSC during interaction with breast cancer cells and co-stimuli not only increased breast cancer growth but also promoted metastatic spreading [92].”
BackgroundFunctional subsets of mesenchymal cell types in the tumor microenvironment
Cortez, E., Roswall, P., & Pietras, K. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.010 · Cited by 116
“Cancer-associated fibroblasts will be considered as a single entity without regarding potential multiplicity caused by the source for recruitment, such as resident fibroblasts, mesenchymal stem cells [17], bone marrow-derived mesenchymal progenitors [18] or circulating fibrocytes [19].”
BackgroundTumor-educated mesenchymal stem cells promote pro-metastatic phenotype
Hill, B. S., Pelagalli, A., Passaro, N., & Zannetti, A. (2017) · Oncotarget · doi:10.18632/oncotarget.20265 · Cited by 104
Le, N. H., Franken, P., & Fodde, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604401 · Cited by 117
N. Momin, E., Vela, G., A. Zaidi, H., & Quinones-Hinojosa, A. (2010) · Current Immunology Reviews · doi:10.2174/157339510791111718 · Cited by 103
“Although MSCs have been shown to enhance metastatic potential in an animal model of breast carcinoma [43], there have been no reports of tumor seeding by MSCs in normal, non-cancerous tissue.”
BackgroundThe Cancer Stem Cell Hypothesis: A Guide to Potential Molecular Targets
Allegra, A., Alonci, A., Penna, G., Innao, V., Gerace, D. G., Rotondo, F., & Musolino, C. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.958231 · Cited by 117
MSCs vs. iPSCs: Potential in therapeutic applications
Thanaskody, K., Jusop, A. S., Tye, G. J., Zaman, W. S. W. K., Dass, S. A., & Nordin, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1005926 · Cited by 115
“The ability of MSCs to suppress the immune system contributes to the growth and spread of tumor cells (Karnoub et al., 2007).”
BackgroundMesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment
Darestani, N. G., Rudova, A., Al-Gazally, M. E., Zekiy, A. O., Ansari, M. J., Zabibah, R. S., Jawad, M. A., Al-Shalah, S. A. J., Rizaev, J. A., Alnassar, Y. S., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-022-01012-0 · Cited by 115
Recruited Brain Tumor‐Derived Mesenchymal Stem Cells Contribute to Brain Tumor Progression
Behnan, J., Isakson, P., Joel, M., Cilio, C., Langmoen, I. A., Vik‐Mo, E. O., & Badn, W. (2014) · STEM CELLS · doi:10.1002/stem.1614 · Cited by 107
“However, their role in brain tumor growth is not well understood as they can both accelerate and inhibit tumor growth [15-17].”
BackgroundThe potential to target CCL5/CCR5 in breast cancer
Velasco-Velázquez, M., Xolalpa, W., & Pestell, R. G. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.949238 · Cited by 107
“Accordingly, the authors suggest that after recruitment of MSCs populations into primary tumors, consequent interactions between the MSCs and breast cancer cells endow the latter with metastatic properties [39].”
BackgroundInfluentialBianchi, G., Borgonovo, G., Pistoia, V., & Raffaghello, L. (2011) · PubMed · doi:10.14670/hh-26.941 · Cited by 115
“This enhanced metastatic ability is dependent on the chemokine CCL5, which is secreted by MSCs and increases the motility, invasion and metastasis of tumour cells (Karnoub et al., 2007).”
BackgroundInfluentialNetwork-based analysis of comorbidities risk during an infection: SARS and HIV case studies
Moni, M. A., & Liò, P. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-333 · Cited by 107
“We have considered 10 different data sets for our analysis (accession numbers are GSE1739, GSE45042, GSE17400, GSE9006, GSE9128, GSE15072, GSE7158, GSE8977, GSE18464 and GSE7621) [32, 55, 57, 64, [78] [79] [80] [81] [82] .”
MicroRNA-mediated breast cancer metastasis: from primary site to distant organs
Wang, L., & Wang, J. (2011) · Oncogene · doi:10.1038/onc.2011.444 · Cited by 115
Cell communication by tunneling nanotubes: Implications in disease and therapeutic applications
Mittal, R., Karhu, E., Wang, J., Delgado, S., Zukerman, R. J., Mittal, J., & Jhaveri, V. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27072 · Cited by 114
“Meanwhile, in the tumor microenvironment, MSCs promote the growth and metastasis of cancer cells (Jung et al., 2013; Karnoub et al., 2007; Rattigan, Hsu, Mishra, Glod, & Banerjee, 2010).”
BackgroundMesenchymal stem cells at the intersection of cell and gene therapy
Myers, T. J., Granero‐Moltó, F., Longobardi, L., Li, T., Yan, Y., & Spagnoli, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.531257 · Cited by 114
“Several examples of the angiogenic effects of MSCs have been presented above and VEGF from MSCs aided in the growth of Burkitt’s lymphoma cells, while secretion of chemokines could promote tumor metastasis [183,188].”
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 114
Tumour progression and metastasis
Arvelo, F. A., Sojo, F. J., & Cotte, C. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.617 · Cited by 115
“CCL5 is secreted by mesenchymal stem cells (MSC) that also act through the CCR5 receptor expressed by breast cancer cells, increasing the invasion and metastasis [67].”
BackgroundEiró, N., González, L. O., Fraile, M., Cid, S., Schneider, J., & Vizoso, F. J. (2019) · Cancers · doi:10.3390/cancers11050664 · Cited by 113
Neutrophil: A New Player in Metastatic Cancers
Wu, M., Ma, M., Tan, Z., Zheng, H., & Liu, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.565165 · Cited by 113
“Mesenchymal stromal cells (MSCs) can also infiltrate into TME to recruit neutrophils (64).”
BackgroundCCL5/CCR5 axis promotes the motility of human oral cancer cells
Chuang, J., Yang, W., Chen, H., Huang, C., Tan, T., Lin, Y., Hsu, C., Fong, Y., & Tang, C. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21783 · Cited by 113
“Interaction of CCL5 with its specific receptor CCR on the surface of cancer cells has been reported to induce cancer invasion (Ben-Baruch, 2006; Karnoub et al., 2007).”
BackgroundAdult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence
Rhodes, L. V., Muir, S. E., Elliott, S., Guillot, L. M., Antoon, J. W., Penfornis, P., Tilghman, S. L., Salvo, V. A., Fonseca, J. P., Lacey, M. R., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0458-2 · Cited by 110
“[12] proposed that the metastatic traits of breast cancer cells are acquired through exposure of the epithelial cells to mesenchymal cells in the tumor-associated stroma.”
BackgroundSuppression of survival signalling pathways by the phosphatase PHLPP
O’Neill, A., Niederst, M. J., & Newton, A. C. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08537.x · Cited by 114
Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor
Halpern, J. L., Kilbarger, A., & Lynch, C. C. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.04.018 · Cited by 101
“The MSC-secreted chemokine CCL5 (RANTES) was found to increase the motility, invasion, and lung metastasis of breast cancer cell lines by binding to CCR5 on cancer cells and initiating reversible phenotypic changes [7].”
BackgroundInfluentialMesenchymal stem cell-derived exosomes facilitate nasopharyngeal carcinoma progression.
Shi, S., Zhang, Q., Xia, Y., You, B., Shan, Y., Bao, L., Li, L., You, Y., & Gu, Z. (2016) · PubMed Central · Cited by 113
Song, K.-H., Park, M. S., Nandu, T. S., Gadad, S. S., Kim, S.-C., & Kim, M. (2016) · Nature Communications · doi:10.1038/ncomms13796 · Cited by 113
Devarajan, E., Song, Y., Krishnappa, S., & Alt, E. (2012) · International Journal of Cancer · doi:10.1002/ijc.26493 · Cited by 100
“Bone marrow-derived mesenchymal stem cells (MSCs) contribute to tumorigenesis by producing cytokines and growth factors.(9) We recently showed that adipose tissue-derived stem cells (ASCs) contribute to the growth and progression of breast cancer cells.”
BackgroundLiu, W.-R., Tian, M., Yang, L., Lin, Y., Jin, L., Ding, Z., Shen, Y., Peng, Y., Gao, D., Zhou, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2749 · Cited by 112
“We also analyzed the gene expression profiles of other cancers and found that the PKM2 mRNA levels were also elevated in breast cancer [15], lung cancer [16], colon cancer [17] (Fig.”
Die hard: Are cancer stem cells the Bruce Willises of tumor biology?
Fábián, Á., Barok, M., Vereb, G., & Szöllõsi, J. (2008) · Cytometry Part A · doi:10.1002/cyto.a.20690 · Cited by 112
“ing clear that several properties, which we thought were intrinsic to CSCs are modulated by the microenvironment of the cancer cells (83), and such key traits as metastasizing (84) and growth (85) may depend on the normal stromal cells that interact with the cancer cells (86).”
BackgroundDu, T., Ju, G., Wu, S., Cheng, Z., Cheng, J., Zou, X., Zhang, G., Miao, S., Liu, G., & Zhu, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096836 · Cited by 100
Breast Cancer Stem Cells: Current Advances and Clinical Implications
Luo, M., Clouthier, S. G., Deol, Y. S., Liu, S., Nagrath, S., Azizi, E., & Wicha, M. S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2519-3_1 · Cited by 114
De Luca, A., Lamura, L., Gallo, M., Maffia, V., & Normanno, N. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24212 · Cited by 102
“MSC-derived monocyte chemotactic protein-1 (MCP-1/CCL2) and interleukin 17B (IL-17B) have been also demonstrated to promote breast cancer cell migration [Molloy et al., 2009; Goldstein et al., 2010].”
BackgroundTherapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
Timaner, M., Letko-Khait, N., Kotsofruk, R., Benguigui, M., Beyar-Katz, O., Rachman-Tzemah, C., Raviv, Z., Bronshtein, T., Machluf, M., & Shaked, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1547 · Cited by 101
“Gemcitabine-educated MSCs promote TIC enrichment via the CXCL10-CXCR3 signaling pathway Several cytokines and growth factors have been shown to promote TIC enrichment, including those secreted by MSCs (29-31).”
BackgroundMicrofluidics-based devices: New tools for studying cancer and cancer stem cell migration
Huang, Y., Agrawal, B., Sun, D., Kuo, J. S., & Williams, J. C. (2011) · Biomicrofluidics · doi:10.1063/1.3555195 · Cited by 105
Clark, E. S., Brown, B. T., Whigham, A. S., Kochaishvili, A., Yarbrough, W. G., & Weaver, A. M. (2008) · Oncogene · doi:10.1038/onc.2008.389 · Cited by 111
“For example, recent studies have shown that diffusible substances can result in a variety of outcomes, such as preparation of metastatic niches, recruitment of mesenchymal stem cells, angiogenesis and tumor progression (Gabrilove, 2001; Ostman, 2004; Hiratsuka et al., 2006; Karnoub et al., 2007).”
Moving Forward in Human Mammary Stem Cell Biology and Breast Cancer Prognostication Using ALDH1
Balicki, D. (2007) · Cell stem cell · doi:10.1016/j.stem.2007.10.015 · Cited by 111
The Role of Adipose-Derived Stem Cells in Breast Cancer Progression and Metastasis
Schweizer, R., Tsuji, W., Gorantla, V. S., Marra, K. G., Rubin, J. P., & Plock, J. A. (2015) · Stem Cells International · doi:10.1155/2015/120949 · Cited by 110
“described previously that BM-MSCs produce RANTES when stimulated by BCCs, which in turn enhances their motility and favors metastasizing [26].”
BackgroundInfluentialVaish, U., Jain, T., Are, A. C., & Dudeja, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413408 · Cited by 111
“However, besides fibroblasts, mesenchymal stem cells (MSCs) [27,28], mesothelial cells (through mesothelial–mesenchymal transition or MMT) [29], adipocytes [30], hematopoietic stem cells [31], and circulating bone marrow cells called fibrocytes [32], have also been shown to transform into CAFs (Figure 1).”
BackgroundApoptosis‐induced cancer cell fusion: a mechanism of breast cancer metastasis
Noubissi, F. K., Harkness, T., Alexander, C. M., & Ogle, B. M. (2015) · The FASEB Journal · doi:10.1096/fj.15-271098 · Cited by 105
“MSCs are known to be present in both healthy and cancerous breast tissue (51, 52) and have even been observed trafficking directly from bone marrow to sites of primary breast tumors (53).”
BackgroundMicroengineering methods for cell-based microarrays and high-throughput drug-screening applications
Xu, F., Wu, J., Wang, S., Durmus, N. G., Gurkan, U. A., & Demirci, U. (2011) · Biofabrication · doi:10.1088/1758-5082/3/3/034101 · Cited by 98
“, angiogenesis [30], metastasis [33], invasiveness [34]) and represent an important target for cancer therapies [35].”
BackgroundStem cells as vectors for antitumour therapy
Loebinger, M. R., & Janes, S. M. (2010) · Thorax · doi:10.1136/thx.2009.128025 · Cited by 109
“MSCs have also been shown to secrete the chemokine CCL5 which promoted metastasis of breast cancer cells in a mouse subcutaneous xenograft model.(85) The production of IL6 by MSCs was also implicated in the increased growth of breast cancer cells by STAT-3 phosphorylation and signalling.”
BackgroundA top-down view of the tumor microenvironment: structure, cells and signaling
Bhome, R., Bullock, M. D., Al Saihati, H. A., Goh, R. W., Primrose, J. N., Sayan, A. E., & Mirnezami, A. H. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00033 · Cited by 98
“Once recruited to the TME, stromal MSCs secrete CCL5 (RANTES) and enhance the metastatic capability of breast cancer cells (Karnoub et al., 2007).”
BackgroundTissue engineered humanized bone supports human hematopoiesis in vivo
Holzapfel, B. M., Hutmacher, D. W., Nowlan, B., Barbier, V., Thibaudeau, L., Theodoropoulos, C., Hooper, J. D., Loessner, D., Clements, J. A., Russell, P. J., et al. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.057 · Cited by 109
Cell-mediated delivery of synthetic nano- and microparticles
Ayer, M., & Klok, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.048 · Cited by 109
de la Torre, P., Pérez-Lorenzo, M. J., Alcázar-Garrido, Á., & Flores, A. I. (2020) · Molecules · doi:10.3390/molecules25030715 · Cited by 94
“Although some studies have proven that MSCs have pro-tumorigenic effects, increasing tumor growth and metastasis [102], it is generally agreed that MSCs can be manipulated with anticancer genes to be used in cancer therapies (Figure 2).”
BackgroundMesenchymal stem cells in cancer progression and anticancer therapeutic resistance
Xuan, X., Tian, C., Zhao, M., Sun, Y., & Huang, C. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02300-4 · Cited by 110
“In breast cancer, cancer cells induce production of CCL5 (also called RANTES) from MSCs via interacting with CCR5, increasing cancer cell motility, invasion, and metastasis in vitro and in vivo [60].”
BackgroundActivation of autophagy in mesenchymal stem cells provides tumor stromal support
Sánchez, C. G., Penfornis, P., Oskowitz, A., Boonjindasup, A. G., Cai, D. Z., Dhule, S. S., Rowan, B. G., Kelekar, A., Krause, D. S., & Pochampally, R. R. (2011) · Carcinogenesis · doi:10.1093/carcin/bgr029 · Cited by 109
Effect of CCL5 expression in the recruitment of immune cells in triple negative breast cancer
Araujo, J. M., Gomez, A. C., Aguilar, A., Salgado, R., Balko, J. M., Bravo, L., Doimi, F., Bretel, D., Morante, Z., Flores, C., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23099-7 · Cited by 108
Metabolic exchanges within tumor microenvironment
Chiarugi, P., & Cirri, P. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.027 · Cited by 109
Hussain, A., Voisin, V., Poon, S., Karamboulas, C., Bui, N. H. B., Meens, J., Dmytryshyn, J., Ho, V. W., Tang, K. H., Paterson, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191094 · Cited by 109
Cheng, Y., Wang, S. B., Liu, J. H., Jin, L., Liu, Y., Li, C. Y., Su, Y., Liu, Y. R., Sang, X., Wan, Q., et al. (2020) · Cell Proliferation · doi:10.1111/cpr.12865 · Cited by 108
Clarke, M. R., Imhoff, F. M., & Baird, S. K. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22178 · Cited by 108
“However, studies in which MSCs are co-injected into animals together with tumor cells have implied that both metastasis promotion and inhibition effects are occurring [9,10,12,13].”
BackgroundThe IL-6 feed-forward loop: A driver of tumorigenesis
Chang, Q., Daly, L., & Bromberg, J. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.007 · Cited by 108
Li, G., Ye, Q., Xue, Y., Sun, H., Zhou, H., Ren, N., Jia, H., Shi, J., Wu, J., Dai, C., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01738.x · Cited by 103
Epithelial cell guidance by self-generated EGF gradients
Scherber, C. M., Aranyosi, A. J., Kulemann, B., Thayer, S. P., Toner, M., Iliopoulos, O., & Irimia, D. (2012) · Integrative Biology · doi:10.1039/c2ib00106c · Cited by 108
Evidences of Early Senescence in Multiple Myeloma Bone Marrow Mesenchymal Stromal Cells
André, T., Meuleman, N., Stamatopoulos, B., De Bruyn, C., Pieters, K., Bron, D., & Lagneaux, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059756 · Cited by 107
Toward Brain Tumor Gene Therapy Using Multipotent Mesenchymal Stromal Cell Vectors
Bexell, D., Scheding, S., & Bengzon, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.58 · Cited by 107
MT1-MMP controls human mesenchymal stem cell trafficking and differentiation
Lu, C., Li, X.-Y., Hu, Y., Rowe, R. G., & Weiss, S. J. (2010) · Blood · doi:10.1182/blood-2009-06-228494 · Cited by 103
Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy
Saigusa (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.906 · Cited by 100
Fischer, E., Chaitanya, K., Wüest, T., Wadle, A., Scott, A. M., van den Broek, M. F., Schibli, R., Bauer, S., & Renner, C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0644 · Cited by 107
The non-coding transcriptome as a dynamic regulator of cancer metastasis
Crea, F., Clermont, P., Parolia, A., Wang, Y. Z., & Helgason, C. D. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9455-3 · Cited by 106
Teng, I.-W., Hou, P.-C., Lee, K.-D., Chu, P.-Y., Yeh, K.-T., Jin, V. X., Tseng, M.-J., Tsai, S.-J., Chang, Y.-S., Wu, C.-S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3418 · Cited by 98
“Bone marrow-derived MSCs are known to play important roles in cancer progression and metastasis (33-35).”
BackgroundEndothelial cells promote triple‐negative breast cancer cell metastasis via PAI‐1 and CCL5 signaling
Zhang, W., Xu, J., Fang, H., Tang, L., Chen, W., Sun, Q., Zhang, Q., Yang, F., Sun, Z., Cao, L., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700237rr · Cited by 106
TGFβ-Directed Therapeutics: 2020
Teicher, B. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107666 · Cited by 109
Chlorogenic acid: Potential source of natural drugs for the therapeutics of fibrosis and cancer
Nwafor, E.-O., Lü, P., Zhang, Y., Liu, R., Peng, H., Xing, B., Liu, Y., Li, Z., Zhang, K., Zhang, Y., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101294 · Cited by 107
“The significant EMT-associated transcription factors, ZEB, TWIST, bHLH, and SNAIL, inhibits the level of epithelial proteins involving E-cadherin, and activate protein expression related with mesenchymal phenotypes like N-cadherin, Vimentin, MMP9, Fibronectin, and MMP2 [164, 165].”
BackgroundAnti‐tumour immunotherapy with V γ9 V δ2 T lymphocytes: from the bench to the bedside
Braza, M. S., & Klein, B. (2012) · British Journal of Haematology · doi:10.1111/bjh.12090 · Cited by 106
“Many tumours, particularly solid ones, contain MSC that secrete high amounts of PGE2 and might therefore escape Vc9Vd2 T cell cytotoxicity (Beyer & Schultze, 2006; Hall et al, 2007; Karnoub et al, 2007; Martinet et al, 2010; Iovino et al, 2011).”
BackgroundCytokine Regulation of Metastasis and Tumorigenicity
Yao, M., Brummer, G., Acevedo, D. S., & Cheng, N. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.005 · Cited by 106
Lineage Commitment, Signaling Pathways, and the Cytoskeleton Systems in Mesenchymal Stem Cells
Saidova, A. A., & Vorobjev, I. A. (2019) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2019.0250 · Cited by 106
Raghavan, S. A., Snyder, C. S., Wang, A., McLean, K., Zamarin, D., Buckanovich, R. J., & Mehta, G. (2020) · Cancers · doi:10.3390/cancers12082063 · Cited by 105
The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression
Gao, D., & Mittal, V. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.06.006 · Cited by 106
Metadata
- Authors
- Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A.
- Affiliations
- Whitehead Institute for Biomedical Research (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Weinberg, Robert A.
- Venue
- Nature
- Published
- 2007-10-04
- Volume
- 449
- Issue
- 7162
- Pages
- 557-563
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2141815918
- Cited by
- 3,206
- References
- 36
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 95 · 2023: 137 · 2022: 144 · 2021: 186 · 2020: 192 · 2019: 153 · 2018: 145 · 2017: 176 · 2016: 182 · 2015: 222 · 2014: 232 · 2013: 232 · 2012: 216
- FWCI
- 89.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P50CA089393, R01CA116235)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- mesenchymal stem cells, breast cancer metastasis, tumor stroma, RANTES, CCR5, paracrine signaling, tumor cell motility, tumor invasion, tumor microenvironment, bone marrow-derived stem cells, tumor xenografts
- MeSH terms
- Animals, Breast Neoplasms, Cell Movement, Fibroblasts, Humans, Lung Neoplasms, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, Mice, SCID, Mice, Inbred NOD, Stromal Cells, Carcinoma, Ductal, Breast, Chemokine CCL5, Receptors, CCR5, Chemokines, CC, Paracrine Communication, Mesenchymal Stem Cell Transplantation, Cell Line, Tumor, Mice, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.